Journal Issue: Volume: 22 No. 2 (2024)
Loading...
Volume
Number
Issue Date
2024
Journal Title
Journal ISSN
ISSN 2091-0231 eISSN 2091-167X
Journal Volume
Articles
The Emerging World of JAK Inhibitors
(Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON), 2024) Uprety, Shraddha
Abstract:
The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several cytokine pathways. Dysregulation in these cytokine pathways is responsible for disorders like alopecia areata, psoriasis, vitiligo, lichen planus, and more in dermatology. Contrary to the injectable biologics, these Janus kinase inhibitors can be taken per oral route and have greater patient acceptability. In this review, we seek to discuss the various indications of Janus Kinase inhibitors and their side effects. We also strive to discuss the monitoring for this class of drugs.
Sleep Disruption in Parents of Children with Atopic dermatitis: A Cause of Concern
(Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON), 2024) Kansal, Naveen Kumar; Chawla, Omna
Abstract:
It is well-established that the physical, mental, and cognitive health of an individual depends on proper sleep. However, regular sleep patterns are likely disrupted in persons who care for persons with chronic illnesses. Atopic dermatitis is a common, chronic inflammatory cutaneous disease affecting a sizeable proportion of the pediatric population. Most parents experience stress while caring for atopic dermatitis in their children. It is a time-intensive and emotionally demanding situation that adversely affects sleep and leads to exhaustion and worry. Sleep disruption of parents further contributes to difficulty coping with dermatitis management and parenting demands. This brief review aims to identify the extent and nature of sleep disruption in parents of atopic children and interventions to address the same.
Evaluation of Serum Cortisol Level in Chronic Superficial Dermatophytosis
(Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON), 2024) Dubey, Varsha; Rastogi, Madhur Kant; Mishra, Nitin; Gahalaut, Pratik; Singh, Amar; Dudea, Aaruj
Abstract:
Introduction: The epidemic-like scenario of superficial fungal infections in India has been complicated by the rampant use of systemic and topical potent steroids. In this study, we hypothesize that the unjudicial use of topical corticosteroids can cause Hypothalamic pituitary axis suppression in chronic dermatophytosis patients.
Objectives: To estimate morning serum cortisol levels in chronic superficial dermatophytosis patients.
Materials and Methods: A total of 208 individuals were enrolled in this study. In which, 104 (50%) patients had Chronic superficial dermatophytosis (case group) and 104 (50%) patients were healthy (control group). Their clinical details and laboratory investigations including KOH and serum cortisol, were recorded on a pre-designed proforma.
Results: The mean S. Cortisol level was 7.27±5.34 μg/ml in cases and 11.21±5.92 μg/ml in the control group. The mean S. Cortisol level was significantly lower in cases as than controls (p <0.001).Conclusion: This study shows that patients with chronic superficial dermatophytosis have low serum cortisol compared to healthy controls.
A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study
(Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON), 2024) Aryal, Alisha; Bhattarai, Niraj; Poudel, Ramesh Sharma; Jha, Smita; Shris, Nupendra
Abstract:
Introduction: Psoriasis is a common skin presentation in dermatology OPD. Methotrexate and apremilast are frequently used for the management of chronic plaque psoriasis.
Objectives: To compare the efficacy and safety of methotrexate versus apremilast for the management of chronic plaque psoriasis
Materials and Methods: This was an interventional study conducted among 41 patients. The patients were divided into 2 groups. Group A received apremilast 10-30mg twice daily, and group B received methotrexate 10-15mg once weekly for 16 weeks. The patients were evaluated at 4, 8 and 16 weeks. PASI score, DLQI score and adverse effects were documented in every follow-up.
Results: The PASI score significantly reduced from 17.22 ± 8.61 (baseline) to 3.90 ± 2.92 (16 weeks) in group A and 18.64 ± 9.02 (baseline) to 5.95 ± 2.89 (16 weeks) in groups B (P = < 0.001). At 16 weeks, the mean PASI score (3.90 ± 2.92) in group A was significantly less than group B (5.95 ± 2.89) (P = 0.02). The percentage reduction of mean PASI from baseline to 16 weeks was 77% in group A and 68.07% in group B. PASI 75 was achieved by 11 patients (52.30 %) in group A and 8 patients (40 %) in group B at 16 weeks. Both groups had a significant decrease in DLQI as compared to baseline at 16 weeks, with insignificant differences between the two groups during each visit. No severe side effects were seen in both groups.
Conclusion: Both treatments can be considered in treating chronic plaque psoriasis. However, apremilast showed more efficacy than methotrexate.
Clinico-bacteriological Study and Antibiotic Sensitivity Pattern in Pyodermas at a Tertiary Care Hospital of Kathmandu
(Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON), 2024) Rayamajhi, Buddha; Das, Anil Kumar; Paudel, Upama
Abstract:
Introduction: Pyodermas are common cutaneous bacterial infections caused mainly by Staphylococci. The causative organisms and their antibiotic sensitivity patterns are changing periodically.
Objectives: The study’s objectives were to determine the clinical and bacteriological profile in pyodermas and the antibiotic sensitivity pattern of isolated organisms.
Materials and Methods: It was a descriptive study conducted at the Department of Dermatology and Venereology and Department of Microbiology, Tribhuvan University Teaching Hospital, from October 2020 to September 2021, in patients with pyodermas. After history taking and examination,the swab was sent for culture and sensitivity. The details of isolated organisms and antibiotic sensitivity patterns were recorded.
Results: Eighty-five patients were included in this study, 55(64.7%) males and 30(35.3%) females. The typical age group affected was 15-24 years. Lower extremities were the most common sites involved. Primary pyodermas were more common than secondary pyodermas, 45(52.9%) vs 40(47.1%).Folliculitis was the most common diagnosis in 22(25.9%) patients. Staphylococcus aureus was the most common organism isolated in 46(54.1%) cases, among which 41 isolates were methicillin-sensitive while 5 isolates were methicillin-resistant. The second most common organism was coagulase-negative Staphylococciin 25(29.4%) cases. Staphylococcus aureus was most sensitive to cephalexin and cloxacillin in 41(89.1%) cases. Coagulase negative Staphylococci were most sensitive to gentamicin in 25(100%) and ciprofloxacin in 24(96.0%) isolates.
Conclusion: The change in the drug sensitivity pattern in the isolates of pyoderma warrants regular monitoring and judicious use of antibiotics to prevent the further disastrous development of drug-resistant strains of organisms.